| Literature DB >> 35293043 |
Nabi Jomehzadeh1, Khadijeh Ahmadi1, Mozhdeh Amiri Bahmanshiri1.
Abstract
BACKGROUND: Extensive and inappropriate use of quinolones has led to growing resistance rates to these broad-spectrum antibiotics. The present study purposed to investigate the prevalence of plasmid-mediated quinolone resistance (PMQR) genes in Klebsiella pneumoniae clinical isolates.Entities:
Keywords: zzm321990Klebsiella pneumoniaezzm321990; PMQR; integrons; minimum inhibitory concentration; quinolones
Mesh:
Substances:
Year: 2022 PMID: 35293043 PMCID: PMC9279965 DOI: 10.1002/jcla.24342
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 3.124
Multiplex PCR primers used to detect PMQR and integrase genes
| Gene | Primer Sequence (5′→3′) | Size of product | PCR conditions | Reference |
|---|---|---|---|---|
|
|
TCAGCAAGAGGATTTCTCA GGCAGCACTATTACTCCCA | 516 | 94°C, 7 min; 35 cycles of 94°C for 50 s, 53°C, 40 s, 72°C, 1 min, final extension 72°C, 5 min. |
|
|
|
GATCGTGAAAGCCAGAAAGG ACGATG CCTGGTAGTTGTCC | 469 | ||
|
|
ACGACATTCGTCAACTGCAA TAAATTGGCACCCTGTAGGC | 417 | ||
|
|
TTGGAAGCGGGGACGGAM ACACGGCTGGACCATA | 260 | 94°C, 2 min; 35 cycles of 94°C for 30 s, 55°C, 30 s, 72°C, 2 min, final extension 72°C, 5 min. |
|
|
|
GCAGGTCCAGCAGCGGGTAG CTTCCTGCCCGAGTATCGTG | 199 | ||
|
|
AACCTCGTCTCCCGTGAAGAGTGG TGAACGCTCTCCACCGCTTCAA | 392 | 95°C, 10 min; 30 cycles of 94°C for 1 min, 55°C, 2 min, 72°C, 4 min, final extension 72°C, 10 min. |
|
|
|
CAGCTCAACAATAAGGATGCGGTC GGAGATCAGGAAATCGCTCTCCTG | 512 | ||
|
|
GTTCGGTCAAGGTTCTG GCCAACTTTCAGCACATG | 920 | 94°C, 2 min; 30 cycles of 94°C for 1 min, 50°C, 1 min, 72°C, 30 s, final extension 72°C, 5 min. |
|
|
|
ATGTCTAACAGTCCATTTTT AAATCTTTAACCCGCAAAC | 420 |
Antibiotic susceptibility pattern of Klebsiella pneumoniae isolates
| Antibiotics | Susceptible (%) | Intermediate (%) | Resistance (%) |
|---|---|---|---|
| Nalidixic Acid | 5 (5.4) | 0 | 87 (94.6) |
| Ciprofloxacin | 72 (78.3) | 3 (3.2) | 17 (18.5) |
| Ofloxacin | 42 (45.6) | 8 (8.7) | 42 (45.6) |
| Levofloxacin | 57 (62) | 7 (7.6) | 28 (30.4) |
| Gatifloxacin | 63 (68.5) | 3 (3.2) | 26 (28.3) |
| Norfloxacin | 50 (54.3) | 2 (2.2) | 40 (43.5) |
| Moxifloxacin | 75 (81.5) | 0 | 17 (18.5) |
Summary of phenotypic and genotypic features of ciprofloxacin non‐susceptible isolates
| Strains (n = 20) | Sample type | PMQR determinant | Integrase gene | FRP | CIP MIC (μg/ml) | TG |
|---|---|---|---|---|---|---|
| K14 | Urine |
|
| NA, CIP, OFX | 8 | − |
| K5 | Urine |
|
| NA, CIP, LVX, NOR | 32 | + |
| K12 | Urine |
|
| NA, CIP, OFX, NOR | 6 | − |
| K55 | Urine |
|
| NA, CIP, OFX, LVX, NOR | 64 | + |
| K24 | Urine |
|
| NA, CIP, LVX | 8 | − |
| K30 | Respiratory |
|
| CIP, OFX, LVX, NOR, GAT | >128 | + |
| K16 | Urine |
|
| NA, CIP | 1.5 | − |
| K62 | Urine |
|
| NA, CIP, NOR, GAT | 32 | + |
| K23 | Urine |
|
| NA, CIP, NOR | 16 | − |
| K47 | Urine |
|
| NA, CIP, OFX, LVX | 16 | − |
| K48 | Urine |
|
| CIP, OFX, NOR | 6 | − |
| K74 | Urine |
|
| CIP, OFX | 1.5 | − |
| K80 | Urine |
|
| NA, CIP, NOR | 3 | − |
| K7 | Wound |
|
| CIP, OFX, LVX, NOR, GAT | >128 | + |
| K36 | Blood |
|
| CIP, OFX, LVX, NOR | 6 | − |
| K89 | Blood |
|
| CIP, LVX, NOR, GAT, MOX | 64 | + |
| K51 | Respiratory |
|
| CIP, OFX, LVX, NOR, GAT, MOX | >128 | + |
| K58 | Urine |
|
| NA, CIP, LVX | 16 | − |
| K76 | Urine |
|
| NA, CIP, OFX | 3 | − |
| K66 | Urine |
|
| NA, CIP | 1.5 | − |
Abbreviations: CIP, ciprofloxacin; FRP, Fluoroquinolone Resistance pattern; GAT, gatifloxacin; LVX, levofloxacin; MOX, moxifloxacin; NA, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; TG, Transconjugant.
FIGURE 1Distribution of plasmid‐mediated quinolone resistance (PMQR) genes among Klebsiella pneumoniae isolates